Art
J-GLOBAL ID：202102217896831418   Reference number：21A0598108

Outlook of IL-6 signaling blockade for COVID-19 pneumonia

COVID-19肺炎に対するIL-6シグナル伝達遮断の展望
Author (1)：
Hashizume Misato

About Hashizume Misato

(Chugai Pharmaceutical Co., Ltd., Tokyo, Japan)

About Chugai Pharmaceutical Co., Ltd., Tokyo, Japan


Material：
Inflammation and Regeneration (Web)

About Inflammation and Regeneration (Web)


Volume： 40  Issue： 1  Page： 1-8  Publication year： 2020 
JST Material Number： U0220A  ISSN： 1880-8190  Document type： Article
Article type： 解説  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)
Thesaurus term：
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
*viral disease

About viral disease

,...
Semi thesaurus term：
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
*COVID-19肺炎

About COVID-19肺炎

,...
Register(free) or Log In to access 

Please login to MyJ-GLOBAL to see full information. You also need to select "Display abstract, etc. of medical articles" in your MyJ-GLOBAL account page in order to see abstracts, etc. of medical articles.

   To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=21A0598108&from=J-GLOBAL&jstjournalNo=U0220A") }}
Author keywords (6)：
Interleukin-6

About Interleukin-6

, 
COVID-19 pneumonia

About COVID-19 pneumonia

, 
Cytokine release syndrome

About Cytokine release syndrome

, 
Tocilizumab

About Tocilizumab

, 
Sarilumab

About Sarilumab

, 
Siltuximab

About Siltuximab

JST classification (2)：
JST classification
Category name(code) classified by JST.
Treatment for infectious diseases,parasitic diseases. 
(GD01030D)

About Treatment for infectious diseases,parasitic diseases.

,  Drug therapy(=pharmacotherapy)for respiratory system diseases 
(GI05020J)

About Drug therapy(=pharmacotherapy)for respiratory system diseases

Substance index (2)：
Substance index
Chemical Substance indexed to the Article.
Lopinavir

About Lopinavir

, 
Methylprednisolone

About Methylprednisolone

Reference (49)：
  • J Immunol.; Regulation of antibody response in vitro. VII. Enhancing soluble factors for IgG and IgE antibody response; T Kishimoto, K Ishizaka; 111; 1973; 1194-1205; citation_id=CR1
  • Nat Rev Rheumatol.; Translating IL-6 biology into effective treatments; EH Choy, F Benedetti, T Takeuchi, M Hashizume, MR John, T Kishimoto; 16; 6; 2020; 335-345; 10.1038/s41584-020-0419-z; citation_id=CR2
  • Int Rev Immunol.; Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights; M Hashizume, SL Tan, J Takano, K Ohsawa, I Hasada, A Hanasaki, I Ito, M Mihara, K Nishida; 34; 3; 2015; 265-279; 10.3109/08830185.2014.938325; citation_id=CR3
  • Nat Rev Drug Discov.; Interleukin-6: designing specific therapeutics for a complex cytokine; C Garbers, S Heink, T Korn, S Rose-John; 17; 6; 2018; 395-412; 10.1038/nrd.2018.45; citation_id=CR4
  • Cytokine.; Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors; M Hashizume, M Mihara; 58; 3; 2012; 424-430; 10.1016/j.cyto.2012.02.010; citation_id=CR5
ｍore...
Terms in the title (6)：
Terms in the title
Keywords automatically extracted from the title.
COVID-19

About COVID-19

, 
肺炎

About 肺炎

, 
IL-6

About IL-6

, 
シグナル伝達

About シグナル伝達

, 
遮断

About 遮断

, 
展望

About 展望


Return to Previous Page

TOP

BOTTOM